Ageing and cancer
PRINCIPAL INVESTIGATORS
- Juan Jesus Martin Liberal
- Joan Maria Viñals Viñals
CLINICAL RESEARCHERS
- Rosa Maria Penin Mosquera
- Diana Perez Sidelnikova
POSTDOCTORAL RESEARCHERS
- Marta Lopez Cerda
- Laura Lorenzo Sanz
PREDOCTORAL RESEARCHERS
- Natalia Perez De Gracia Velazquez
CANCER
ONCOBELL
Scientific production
11
PAPERS
Average IF: 20,93
2
LED PAPERS
Average IF: 6,90
5 PUBLICATIONS IN FIRST DECILE
8 PUBLICATIONS IN FIRST QUARTILE
10 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Martin Liberal,J;Marquez Rodas,I;Cerezuela Fuentes,P;Soria,A;Garicano,F;Medina,J;Galindo,RG et al, Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases, Cancer Treat. Rev., 2025;133; doi:10.1016/j.ctrv.2025.102886
- Melero,I;de Miguel Luken,M;de Velasco,G;Garralda,E;Martín Liberal,J;Joerger,M;Alonso,G et al, Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours., Nature, 2025;637(8048):1218-1227, doi:10.1038/s41586-024-08305-z
- Arance,A;Berciano Guerrero,MA;Guo,J;Carlino,MS;Ascierto,PA;Burotto,M;Mortier,L et al, Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma., Ann. Oncol., 2025;36(12):1535-1546, doi:10.1016/j.annonc.2025.08.008
- Martín Lluesma,S;Dafni,U;Vervita,K;Karlis,D;Dimopoulou,G;Tsourti,Z;Villacampa,G et al, Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis., Ann. Oncol., 2025;36(8):909-919, doi:10.1016/j.annonc.2025.04.001
- Espin,R;Medina Jover,F;Siguenza Andrade,J;Farran Matas,S;Mateo,F;Figueras,A;Sanz,RT et al, Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment, NAR Cancer, 2025;7(1); doi:10.1093/narcan/zcaf007
Research highlights
PROJECTS
5 Ongoing competitive projects
9 Started clinical trials
29 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical guideline
NETWORKS
EuroPDX
AGAUR SGR GRC
Selected projects
- PID2023-149132OB-I00. FACTORES Y MECANISMOS IMPLICADOS EN LA RESISTENCIA A INHIBIDORES DE IMMUNE CHECKPOINT (ICIs) EN cSCC: INFLUENCIA DE UN MICROAMBIENTE TUMORAL ENVEJECIDO. Ministerio de Ciencia e Innovación. Budget: 300.000€. 2024-2027. PI: PURIFICACION MUÑOZ MORUNO.
- PI22/01492. Superar la resistencia al tratamiento con inhibidores de puntos de control inmunitarios en el melanoma cutáneo. Instituto de Salud Carlos III (ISCIII). Budget: 183.920€. 2023-2027. PI: JUAN JESUS MARTIN LIBERAL.
- ICI21/00110. Tratamiento con TILs en tumores avanzados con alteraciones del complejo SWI/SNF: El estudio TILTS. Instituto de Salud Carlos III (ISCIII). Budget: 1.081.914,72€. 2022-2026. PI: JUAN JESUS MARTIN LIBERAL.
- 2021 SGR 00769. “Nuevas terapias para el tratamiento de cáncer de piel. “Novel therapies for skin cancer treatment”. AGENCIA GESTIO D’AJUTS UNIV. I RECERCA. Budget: 40.000€. 2022-2025. PI: PURIFICACION MUÑOZ MORUNO.
- SGZ-2020-13191. “CEMIRESIST. Mechanisms of Resistance to antiPD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.” with Protocol Code SGZ-2020-13191 and whose principal clinic investigator is Dr. Jose Piulats hereinafter “the Trial”). REGENERON . Budget: 365.140€. 2025- . PI: PURIFICACION MUÑOZ MORUNO /JOSEP MARÍA PIULATS RODRÍGUEZ.